Joel Greenblatt Exelixis, Inc. Transaction History

Gotham Asset Management, LLC

$11.5 Billion
Q1 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Exelixis, Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 559,324 shares of EXEL stock, worth $22.8 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

559,324

Previous 427,855 30.73%

Holding current value

$22.8 Million

Previous $14.2 Million 44.94%

% of portfolio

0.18%

Previous 0.14%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$32.38 - $39.16 $4.26 Million - $5.15 Million	131,469 Added 30.73%	559,324 $20.7 Million
Q4 2024 Feb 14, 2025	BUY	$25.39 - $36.46 $3.21 Million - $4.61 Million	126,375 Added 41.92%	427,855 $14.2 Million
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $1.06 Million - $1.33 Million	48,276 Added 19.07%	301,480 $7.82 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $996,090 - $1.16 Million	48,972 Added 23.98%	253,204 $5.69 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $964,872 - $1.14 Million	47,837 Added 30.59%	204,232 $4.85 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $155,694 - $195,163	8,088 Added 5.45%	156,395 $3.75 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $656,232 - $783,756	34,466 Added 30.28%	148,307 $3.24 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $218,984 - $246,824	-12,052 Reduced 9.57%	113,841 $2.18 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $1.95 Million - $2.32 Million	-119,562 Reduced 48.71%	125,893 $2.44 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $2.37 Million - $2.76 Million	158,579 Added 182.53%	245,455 $3.94 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $137,152 - $194,795	8,747 Added 11.2%	86,876 $1.36 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $925,784 - $1.23 Million	53,084 Added 211.95%	78,129 $1.63 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $65,105 - $86,667	3,823 Added 18.01%	25,045 $568,000
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $149,006 - $205,825	-9,407 Reduced 30.71%	21,222 $388,000
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $499,252 - $647,497	30,629 New	30,629 $647,000
Q4 2020 Feb 16, 2021	SELL	$18.39 - $24.8 $619,117 - $834,916	-33,666 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $71,022 - $92,565	-3,436 Reduced 9.26%	33,666 $823,000
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $195,956 - $326,435	-11,905 Reduced 24.29%	37,102 $881,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $822,687 - $1.24 Million	-56,894 Reduced 53.72%	49,007 $844,000
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $7.01 Million - $8.74 Million	-462,929 Reduced 81.38%	105,901 $1.87 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $6.99 Million - $8.95 Million	395,308 Added 227.81%	568,830 $10.1 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $291,484 - $381,100	15,398 Added 9.74%	173,522 $3.71 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $648,015 - $818,615	33,062 Added 26.44%	158,124 $3.76 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $988,997 - $1.58 Million	72,454 Added 137.72%	125,062 $2.46 Million
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $1.42 Million - $2 Million	-89,450 Reduced 62.97%	52,608 $932,000
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $1.82 Million - $2.21 Million	-98,268 Reduced 40.89%	142,058 $3.06 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $4.3 Million - $6.19 Million	-193,983 Reduced 44.66%	240,326 $5.32 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $10.5 Million - $13.4 Million	-432,780 Reduced 49.91%	434,309 $13.2 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $20.2 Million - $25.4 Million	867,089	867,089 $21 Million

Others Institutions Holding EXEL

# of Institutions

613

Shares Held

257M

Call Options Held

1.57M

Put Options Held

730K

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $13.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account